EUCTR2020-000314-15-Outside-EU/EEA
Active, not recruiting
Phase 1
Open label exploratory study to evaluate the effect of dupilumab on skin barrier function in patients with moderate to severe atopic dermatitis - BALISTAD
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Atopic dermatitis
- Sponsor
- Sanofi-Aventis Recherche & Développement
- Status
- Active, not recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Participant must be between 12 to 65 years of age (inclusive), at the time of signing the informed consent.
- •Atopic dermatitis patients:
- •\- Male or female patients.
- •\- Patients with AD diagnosis according to Hanifin and Rajka criteria at least 1 year before screening.
- •\- IGA score of \=3 at screening (on the 0\-4 scale).
- •\- Patients with moderate to severe atopic dermatitis that are eligible to be treated with dupilumab according to product monograph
- •\- Patients with AD must have active lesions on the upper limbs or lower limbs, with severity for lesion erythema or edema/papulation \=2 at screening on the 0\-3 scale of the ISS.
- •\- Participants should have a non\-lesional (normal looking) skin area 4 cm from the edge of the lesional area. If unable to identify non\-lesional skin 4 cm from the lesional area, it is acceptable to identify normal looking skin as close to the lesion as possible.
- •Healthy volunteers:
- •\- Age and gender matched to a selected AD patient. Adolescents aged 12 to 17 years will be matched by post puberty status, and adults aged 18 to 65 years will be matched by age as close as possible within 10 years of age..
Exclusion Criteria
- •\- Previous treatment with dupilumab within 6 months prior to screening
- •\- Skin conditions other than AD that can confound assessments in the area of TEWL assessments in the opinion of the investigator (ie, skin atrophy, ichthyosis, Netherton syndrome, severe photo damage).
- •\- Cracked, crusted, oozing, or bleeding AD lesions in the designated lesional assessment area leaving insufficient skin that is adequate for TEWL assessments.
- •\- Ocular disorder that in the opinion of the investigator could adversely affect the individual’s risk for study participation. Examples include \-but are not limited to\- individuals with a history of active cases of herpes keratitis; Sjogren’s syndrome, keratoconjunctivitis sicca or dry eye syndrome that require daily use of supplemental lubrication; or individuals with ocular conditions that require the use of ocular corticosteroids or cyclosporine.
- •\- Healthy volunteers with a personal history of an atopic condition.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Dupilumab-PEdiatric skin barrier function and LIpidomics STudy in patients with Atopic DermatitisAtopic dermatitisMedDRA version: 20.0Level: PTClassification code 10012438Term: Dermatitis atopicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2020-001518-40-GBSanofi Aventis Recherche & Developpement48
Active, not recruiting
Phase 1
Dupilumab skin BArrier function and LIpidomics STudy in Atopic Dermatitis in ChinaAtopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2024-000164-37-Outside-EU/EEASanofi (China) Investment Co., Ltd, Shanhai Branch
Active, not recruiting
Phase 1
The effects of two brands of hydrocortisone injected intramuscularly into deltoid and thigh musclesAddison's DiseaseMedDRA version: 20.1Level: PTClassification code 10001130Term: Addison's diseaseSystem Organ Class: 10014698 - Endocrine disordersTherapeutic area: Body processes [G] - Metabolic Phenomena [G03]EUCTR2015-001090-40-GBThe London Clinic8
Active, not recruiting
Phase 1
Investigation on the effect and tolerability of erenumab in posttraumatic headachePost-traumatic headacheMedDRA version: 20.0Level: LLTClassification code 10019222Term: Headache post-traumaticSystem Organ Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2018-003943-46-DKDanish Headache Center100
Active, not recruiting
Phase 1
An open label study to evaluate the efficacy and tolerability of erenumab in the management of persistent redness and flushing in rosacea - STOP ROS StudyEUCTR2019-003971-20-DKRigshospitalet Glostrup30